Comprehensive Support Project for Oncology Research
Quick facts
Phase 3 pipeline
- trastuzumab and chemotherapy · Oncology
Trastuzumab blocks HER2 signaling on cancer cells while chemotherapy drugs kill rapidly dividing cells, combining targeted and cytotoxic approaches. - trastuzumab monotherapy · Oncology
Trastuzumab targets and binds to the HER2/neu receptor on cancer cells, triggering an immune response and inhibiting cell growth.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: